Global Biodefense June 28, 2022
A team of researchers in the US (NIAID, industry) has demonstrated that an inactivated, multivalent whole virus vaccine, delivered intramuscularly or intranasally, is broadly protective against challenges with multiple IAV HA/NA subtypes in both mice and ferrets, including challenges with IAV subtypes not contained in the vaccine. This vaccine approach indicates the feasibility of eliciting broad “universal” IAV protection and identifies a promising candidate for influenza vaccine clinical development…read more. Open Access TECHNICAL ARTICLE
Protection with low dose (¼) immunization in mice. Credit: bioArxiv, Posted September 10, 2021.